# US 2021/0332148 A1 · Antigen-binding polypeptides directed against cd38

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0332148 A1
- Document ID: US20210332148A1
- Status: Published application
- Kind: A1
- Application number: 17/119,073
- Filed: 2020-12-11
- Published: 2021-10-28
- Earliest claimed: 2015-11-10
- Assignees: University Medical Center Hamburg-Eppendorf
- Applicants: University Medical Center Hamburg-Eppendorf
- Inventors: Friedrich Nolte; Peter Bannas; Kerstin Schütze; William Fumey; Levin Schriewer; Stephan Menzel; Catelijne Stortelers
- Web page: https://patentgrep.com/patent/US20210332148A1

## CPC

- C07K 16/2896: {against molecules with a "CD"-designation, not provided for elsewhere}
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 11/06: Antiasthmatics
- A61P 13/02: of urine or of the urinary tract, e.g. urine acidifiers
- A61P 13/12: of the kidneys
- A61P 17/00: Drugs for dermatological disorders
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 37/02: Immunomodulators
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- C12N 15/86: Viral vectors
- C12Q 1/25: involving enzymes not classifiable in groups C12Q1/26 {- C12Q1/66}
- G01N 33/53: Immunoassay; Biospecific binding assay; Materials therefor
- A61K 2039/505: {comprising antibodies}
- C07K 2317/22: from camelids, e.g. camel, llama or dromedary
- C07K 2317/31: multispecific
- C07K 2317/64: comprising a combination of variable region and constant region components
- C07K 2317/732: Antibody-dependent cellular cytotoxicity [ADCC]
- C07K 2317/734: Complement-dependent cytotoxicity [CDC]
- C07K 2317/75: Agonist effect on antigen
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The invention relates to polypeptides specifically binding to CD38 and are therefore suitable for the diagnosis and for the therapeutic and prophylactic treatment of diseases which are characterized by increased CD38 expression. Conjugates and pharmaceutical compositions comprising the polypeptides are disclosed as well. In addition, the invention relates to the use of such polypeptides in methods for the detection of CD38 and/or CD38-expressing cells in a biological sample. A process for the purification and concentration of CD38 and/or CD38-expressing cells in which the antigen-binding polypeptides are used are also described.

## Claims

### Claim 1

A polypeptide comprising at least one immunoglobulin single variable domain (ISVD) that specifically binds to an epitope on human CD38 (SEQ ID NO:465) with an EC50 value of less than 200 nM and does not compete with monoclonal anti-CD38 antibody Daratumumab binding to said CD38.

### Claim at position 2

-5. (canceled)

### Claim 6 (depends on 1)

The polypeptide of claim 1, wherein said ISVD specifically binds a first epitope of said CD38 and wherein Daratumumab binds to a second epitope of said CD38, wherein said first epitope and said second epitope are different.

### Claim 7 (depends on 6)

The polypeptide of claim 6, wherein said first epitope and said second epitope do not overlap.

### Claim 8 (depends on 1)

The polypeptide of claim 1, wherein said at least one ISVD is selected from the group consisting of WF152 (SEQ ID NO:1), JK54 (SEQ ID NO:2), WF9 (SEQ ID NO:3), JK36 (SEQ ID NO: 4), JK30 (SEQ ID NO:5), JK24 (SEQ ID NO:6), JK31 (SEQ ID NO:7), JK32 (SEQ ID NO:8), WF32 (SEQ ID NO:9), JK2 (SEQ ID NO:11), JK12 (SEQ ID NO:12), JK14 (SEQ ID NO:13), and JK42 (SEQ ID NO:14).

### Claim 9 (depends on 1)

The polypeptide of claim 1, further comprising a fragment crystallizable portion (Fc portion) linked to said at least one ISVD.

### Claim 10 (depends on 1)

A composition comprising a plurality of polypeptides according to claim 1 and at least one pharmaceutically acceptable carrier, diluent, excipient, and/or adjuvant.

### Claim 11 (depends on 1)

A method of targeting a CD38-expressing cell for treatment of at least one disease, disorder or condition that is associated with CD38, said method comprising administering a pharmaceutically active amount of a polypeptide according to claim 1 to a subject in need thereof.

### Claim 12 (depends on 11)

The method of claim 11, wherein said CD38-expressing cell is a tumor cell.

### Claim 13 (depends on 12)

The method of claim 12, further comprising administering monoclonal anti-CD38 antibody Daratumumab to said subject, wherein said at least one ISVD and said Daratumumab bind to non-overlapping epitopes on CD38 of said tumor cell.

### Claim 14 (depends on 13)

The method of claim 13, wherein said at least one ISVD and said Daratumumab demonstrate a synergistic cytotoxic effect against said CD38-expressing tumor cell.

### Claim 15 (depends on 12)

The method of claim 12, wherein said polypeptide inhibits growth of said tumor cell.

### Claim 16 (depends on 11)

The method of claim 11, wherein said polypeptide comprises at least a second ISVD that specifically binds to an epitope on human CD38, wherein said at least one ISVD binds a first epitope of CD38 and said second ISVD binds a second epitope on CD38, wherein said first epitope is different from said second epitope.

### Claim 17 (depends on 16)

The method of claim 16, wherein said first epitope does not overlap with said second epitope.

### Claim 18 (depends on 16)

The method of claim 16, wherein said at least two ISVDs are directly linked to each other or linked to each other via a linker.

### Claim 19 (depends on 18)

The method of claim 18, in which the linker is selected from the group of linkers with SEQ ID NOs: 482-494.

### Claim 20 (depends on 11)

The method of claim 11, wherein said at least one ISVD is selected from the group consisting of WF152 (SEQ ID NO:1), JK54 (SEQ ID NO:2), WF9 (SEQ ID NO:3), JK36 (SEQ ID NO: 4), JK30 (SEQ ID NO:5), JK24 (SEQ ID NO:6), JK31 (SEQ ID NO:7), JK32 (SEQ ID NO:8), WF32 (SEQ ID NO:9), JK2 (SEQ ID NO:11), JK12 (SEQ ID NO:12), JK14 (SEQ ID NO:13), and JK42 (SEQ ID NO:14).
